TY - JOUR
T1 - Multicenter Comparison of Molecular Tumor Boards in The Netherlands
T2 - Definition, Composition, Methods, and Targeted Therapy Recommendations
AU - Koopman, Bart
AU - Groen, Harry J. M.
AU - Ligtenberg, Marjolijn J. L.
AU - Grünberg, Katrien
AU - Monkhorst, Kim
AU - de Langen, Adrianus J.
AU - Boelens, Mirjam C.
AU - Paats, Marthe S
AU - Von der Thüsen, Jan H
AU - Dinjens, Winand N. M.
AU - Solleveld, Nienke
AU - Van Wezel, Tom
AU - Gelderblom, Hans
AU - Hendriks, Lizza E.
AU - Speel, Ernst-Jan M.
AU - Theunissen, Tom E
AU - Kroeze, Leonie I.
AU - Mehra, Niven
AU - Piet, Berber
AU - van der Wekken, A. J.
AU - Elst, ter, Arja
AU - Timens, Wim
AU - Willems, Stefan M.
AU - Meijers, Ruud W J
AU - De Leng, Wendy W. J.
AU - van Lindert, Anne S. R.
AU - Radonic, Teodora
AU - Hashemi, Sayed M S
AU - Heideman, Danielle A. M.
AU - Schuuring, Ed
AU - van Kempen, L.
N1 - Funding Information: We are grateful to Anke van den Berg, Matthew Groves, Geke Hospers, Birgitta Hiddinga, Hilde Jalving, Lucie Hijmering‐Kappelle, Joost Kluiver, Michel van Kruchten, Elise van der Logt, Maarten Niemantsverdriet, Sjoukje Oosting, Juliana Vilacha, Michel van den Heuvel, Lieneke Steeghs, Ingrid Vogelaar, Linda Bosch, Liudmila Kodach, Egbert Smit, Annette Bijsmans, Maxime van Berge Henegouwen, Hans Morreau, Lisa Hillen, Xiao Fei Li, John Hinrichs, Anne Jansen, Joyce Radersma‐van Loon, and Aryan Vink and all other members of the molecular tumor boards in The Netherlands for their contributions to the conduct and successful completion of this study. This work was supported by ZonMW (The Netherlands Organization for Health Research) within the Personalized Medicine Program (grant number 846001001). Funding Information: We are grateful to Anke van den Berg, Matthew Groves, Geke Hospers, Birgitta Hiddinga, Hilde Jalving, Lucie Hijmering-Kappelle, Joost Kluiver, Michel van Kruchten, Elise van der Logt, Maarten Niemantsverdriet, Sjoukje Oosting, Juliana Vilacha, Michel van den Heuvel, Lieneke Steeghs, Ingrid Vogelaar, Linda Bosch, Liudmila Kodach, Egbert Smit, Annette Bijsmans, Maxime van Berge Henegouwen, Hans Morreau, Lisa Hillen, Xiao Fei Li, John Hinrichs, Anne Jansen, Joyce Radersma-van Loon, and Aryan Vink and all other members of the molecular tumor boards in The Netherlands for their contributions to the conduct and successful completion of this study. This work was supported by ZonMW (The Netherlands Organization for Health Research) within the Personalized Medicine Program (grant number 846001001). Publisher Copyright: © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
PY - 2021/8
Y1 - 2021/8
N2 - Background Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.Materials and Methods MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy.Results Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%).Conclusion MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow.Implications for Practice Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.
AB - Background Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.Materials and Methods MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy.Results Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%).Conclusion MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow.Implications for Practice Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.
KW - Molecular tumor board
KW - Rare mutations
KW - Molecular diagnostics
KW - Decision making
KW - Multidisciplinary
KW - CANCER
KW - ONCOLOGY
KW - GENOMICS
KW - PATHOLOGY
U2 - 10.1002/onco.13580
DO - 10.1002/onco.13580
M3 - Article
C2 - 33111480
SN - 1083-7159
VL - 26
SP - e1347–e1358
JO - The Oncologist
JF - The Oncologist
IS - 8
ER -